载脂蛋白E基因型与性别对阿尔茨海默病的风险因素:一项荟萃分析
结果显示,55-85岁总体男女AD风险无差异,但65-75岁女性风险高于男性;APOE ε2/ε3对女性保护作用更强;MCI风险在55-70岁女性中更高。
要点
- APOE ε3/ε4者55-85岁AD风险男女相近,但65-75岁女性风险更高。
核心结论
- 男女APOE ε3/ε4者在55-85岁AD风险几乎相同,但女性在较年轻时风险增加。
主要发现
- 55-85岁APOE ε3/ε4者AD风险男女无差异:男性OR 3.09(95%CI 2.79-3.42),女性OR 3.31(95%CI 3.03-3.61)。
- 55-85岁MCI风险男女无差异:男性OR 1.55(95%CI 1.36-1.76),女性OR 1.60(95%CI 1.43-1.81)。
临床怎么用
- 评估AD风险时需考虑性别和年龄,尤其65-75岁女性APOE ε3/ε4者风险更高。
- 对携带APOE ε2/ε3的女性可告知其AD保护作用更强。
- 55-70岁女性APOE ε3/ε4者应关注MCI风险。
局限性
- 参与者大多为白人,许多种族/民族信息未收集或未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. OBJECTIVE: To determine how sex and APOE genotype affect the risks for developing MCI and AD. DATA SOURCES: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants. STUDY SELECTION: Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. DATA EXTRACTION AND SYNTHESIS: Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. MAIN OUTCOMES AND MEASURES: Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. RESULTS: Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen. CONCLUSIONS AND RELEVANCE: Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
引用
- Neu SC, Pa J, Kukull W, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol. 2017. PMID: 28846757. doi:10.1001/jamaneurol.2017.2188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。